Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Memory Impairment Predicts Alzheimer's Disease
Self perceived memory impairment is an indicator of pending Alzheimer dementia but not of vascular dementia, according to results of the LADIS (Leukoaraiosis and Disability) study which explores the impact of brain white matter changes on the functioning of independent elderly individuals over a 3 year period. The study is being presented at the current meeting of the European Neurological Society (ENS), a major meeting in European neurology that is gathering more than 2,900 experts from all over the world in Milan.

Research Investigates The Treatment Of Traumatic Brain And Head Injury
The National Institute for Health Research Health Technology Assessment (NIHR HTA) programme is expanding the evidence base surrounding the treatment of traumatic brain and head injury (TBI) by commissioning four new research projects. If left untreated many patients with head injury will rapidly develop complications which may lead to death or permanent disability. More than 100,000 people in the UK have long-term effects caused by such injuries. Prompt medical treatment may prevent the worsening of symptoms and lead to a better outcome.
News of the day
Slicing Chromosomes Leads To New Insights Into Cell Division
By using ultrafast laser pulses to slice off pieces of chromosomes and observe how the chromosomes behave, biomedical engineers at the University of Michigan have gained pivotal insights into mitosis, the process of cell division.
Endocrinology

PolyMedix Receives United States Patent For Angiogenesis Inhibitor Compounds

PolyMedix, Inc. (OTCBB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, announced that the United States Patent and Trademark Office issued a patent assigned to PolyMedix relating to angiogenesis inhibitors. The patent, number 7,553,876, entitled "Polycationic Compounds and Uses Thereof," relates to therapeutic uses of PolyMedix compounds for inhibiting angiogenesis. Angiogenesis is a process involving the growth of new blood vessels. The abnormal growth of new blood vessels is associated with many diseases, including age-related macular degeneration (AMD), the most common form of blindness in the elderly, cancers, and inflammation. Inhibiting abnormal angiogenesis may be useful therapy for these conditions. Lucentis® and Macugen® are two products currently approved for treatment of AMD. PolyMedix"s angiogenesis inhibitors may have a mechanism of action distinct from compounds that only inhibit VEGF (vascular endothelial growth factor). "This is an exciting accomplishment for PolyMedix. This patent represents the first allowance from our applications relating to angiogenesis inhibition, and another compelling example of the efficiency and capabilities of our drug discovery approach," commented Nicholas Landekic, President and Chief Executive Officer. PolyMedix, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009